Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 297

1.

CD20-Specific Immunoligands Engaging NKG2D Enhance γδ T Cell-Mediated Lysis of Lymphoma Cells.

Peipp M, Wesch D, Oberg HH, Lutz S, Muskulus A, van de Winkel JGJ, Parren PWHI, Burger R, Humpe A, Kabelitz D, Gramatzki M, Kellner C.

Scand J Immunol. 2017 Oct;86(4):196-206. doi: 10.1111/sji.12581.

2.

Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells.

Engelberts PJ, Voorhorst M, Schuurman J, van Meerten T, Bakker JM, Vink T, Mackus WJ, Breij EC, Derer S, Valerius T, van de Winkel JG, Parren PW, Beurskens FJ.

J Immunol. 2016 Dec 15;197(12):4829-4837. Epub 2016 Nov 2.

3.

Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30.

Kellner C, Günther A, Humpe A, Repp R, Klausz K, Derer S, Valerius T, Ritgen M, Brüggemann M, van de Winkel JG, Parren PW, Kneba M, Gramatzki M, Peipp M.

Oncoimmunology. 2015 Jun 5;5(1):e1058459. eCollection 2016.

4.

Complement is activated by IgG hexamers assembled at the cell surface.

Diebolder CA, Beurskens FJ, de Jong RN, Koning RI, Strumane K, Lindorfer MA, Voorhorst M, Ugurlar D, Rosati S, Heck AJ, van de Winkel JG, Wilson IA, Koster AJ, Taylor RP, Saphire EO, Burton DR, Schuurman J, Gros P, Parren PW.

Science. 2014 Mar 14;343(6176):1260-3. doi: 10.1126/science.1248943.

5.

IgA EGFR antibodies mediate tumour killing in vivo.

Boross P, Lohse S, Nederend M, Jansen JH, van Tetering G, Dechant M, Peipp M, Royle L, Liew LP, Boon L, van Rooijen N, Bleeker WK, Parren PW, van de Winkel JG, Valerius T, Leusen JH.

EMBO Mol Med. 2013 Aug;5(8):1213-26. doi: 10.1002/emmm.201201929.

6.

Staphylococcus aureus formyl peptide receptor-like 1 inhibitor (FLIPr) and its homologue FLIPr-like are potent FcγR antagonists that inhibit IgG-mediated effector functions.

Stemerding AM, Köhl J, Pandey MK, Kuipers A, Leusen JH, Boross P, Nederend M, Vidarsson G, Weersink AY, van de Winkel JG, van Kessel KP, van Strijp JA.

J Immunol. 2013 Jul 1;191(1):353-62. doi: 10.4049/jimmunol.1203243. Epub 2013 Jun 5.

7.

Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange.

Labrijn AF, Meesters JI, de Goeij BE, van den Bremer ET, Neijssen J, van Kampen MD, Strumane K, Verploegen S, Kundu A, Gramer MJ, van Berkel PH, van de Winkel JG, Schuurman J, Parren PW.

Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):5145-50. doi: 10.1073/pnas.1220145110. Epub 2013 Mar 11.

8.

Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity.

Kellner C, Maurer T, Hallack D, Repp R, van de Winkel JG, Parren PW, Valerius T, Humpe A, Gramatzki M, Peipp M.

J Immunol. 2012 Nov 15;189(10):5037-46. doi: 10.4049/jimmunol.1201321. Epub 2012 Oct 12.

9.

Patients with unstable angina pectoris show an increased frequency of the Fc gamma RIIa R131 allele.

Raaz-Schrauder D, Ekici AB, Munoz LE, Klinghammer L, Voll RE, Leusen JH, van de Winkel JG, Reis A, Schett G, Garlichs CD, Herrmann M.

Autoimmunity. 2012 Nov;45(7):556-64. doi: 10.3109/08916934.2012.682665. Epub 2012 Jun 20.

PMID:
22559288
10.

Enhanced FcαRI-mediated neutrophil migration towards tumour colonies in the presence of endothelial cells.

Otten MA, Bakema JE, Tuk CW, Glennie MJ, Tutt AL, Beelen RH, van de Winkel JG, van Egmond M.

Eur J Immunol. 2012 Jul;42(7):1815-21. doi: 10.1002/eji.201141982.

11.

Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression.

Derer S, Berger S, Schlaeth M, Schneider-Merck T, Klausz K, Lohse S, Overdijk MB, Dechant M, Kellner C, Nagelmeier I, Scheel AH, Lammerts van Bueren JJ, van de Winkel JG, Parren PW, Peipp M, Valerius T.

Neoplasia. 2012 Mar;14(3):190-205.

12.

Retraction for Lammerts van Bueren et al. The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility.

Lammerts van Bueren JJ, Bleeker WK, Brännström A, Jansson M, Peipp M, Schneider-Merck T, Valerius T, van de Winkel JG, Parren PW.

Proc Natl Acad Sci U S A. 2012 Apr 3;109(14):5548. doi: 10.1073/pnas.1203736109. Epub 2012 Mar 19. No abstract available.

13.

Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity.

Kellner C, Hallack D, Glorius P, Staudinger M, Mohseni Nodehi S, de Weers M, van de Winkel JG, Parren PW, Stauch M, Valerius T, Repp R, Humpe A, Gramatzki M, Peipp M.

Leukemia. 2012 Apr;26(4):830-4. doi: 10.1038/leu.2011.288. Epub 2011 Oct 18. No abstract available.

PMID:
22005785
14.

Quantitative analysis of the interaction strength and dynamics of human IgG4 half molecules by native mass spectrometry.

Rose RJ, Labrijn AF, van den Bremer ET, Loverix S, Lasters I, van Berkel PH, van de Winkel JG, Schuurman J, Parren PW, Heck AJ.

Structure. 2011 Sep 7;19(9):1274-82. doi: 10.1016/j.str.2011.06.016.

15.

The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden.

Boross P, Jansen JH, de Haij S, Beurskens FJ, van der Poel CE, Bevaart L, Nederend M, Golay J, van de Winkel JG, Parren PW, Leusen JH.

Haematologica. 2011 Dec;96(12):1822-30. doi: 10.3324/haematol.2011.047159. Epub 2011 Aug 31.

16.

Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.

Repp R, Kellner C, Muskulus A, Staudinger M, Nodehi SM, Glorius P, Akramiene D, Dechant M, Fey GH, van Berkel PH, van de Winkel JG, Parren PW, Valerius T, Gramatzki M, Peipp M.

J Immunol Methods. 2011 Oct 28;373(1-2):67-78. doi: 10.1016/j.jim.2011.08.003. Epub 2011 Aug 9.

PMID:
21855548
17.

Species-specific determinants in the IgG CH3 domain enable Fab-arm exchange by affecting the noncovalent CH3-CH3 interaction strength.

Labrijn AF, Rispens T, Meesters J, Rose RJ, den Bleker TH, Loverix S, van den Bremer ET, Neijssen J, Vink T, Lasters I, Aalberse RC, Heck AJ, van de Winkel JG, Schuurman J, Parren PW.

J Immunol. 2011 Sep 15;187(6):3238-46. doi: 10.4049/jimmunol.1003336. Epub 2011 Aug 12.

18.

Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells.

Beum PV, Peek EM, Lindorfer MA, Beurskens FJ, Engelberts PJ, Parren PW, van de Winkel JG, Taylor RP.

J Immunol. 2011 Sep 15;187(6):3438-47. doi: 10.4049/jimmunol.1101189. Epub 2011 Aug 12.

19.

Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition.

Overdijk MB, Verploegen S, van den Brakel JH, Lammerts van Bueren JJ, Vink T, van de Winkel JG, Parren PW, Bleeker WK.

J Immunol. 2011 Sep 15;187(6):3383-90. doi: 10.4049/jimmunol.1003926. Epub 2011 Aug 10.

20.

Human kappa light chain targeted Pseudomonas exotoxin A--identifying human antibodies and Fab fragments with favorable characteristics for antibody-drug conjugate development.

Kellner C, Bleeker WK, Lammerts van Bueren JJ, Staudinger M, Klausz K, Derer S, Glorius P, Muskulus A, de Goeij BE, van de Winkel JG, Parren PW, Valerius T, Gramatzki M, Peipp M.

J Immunol Methods. 2011 Aug 31;371(1-2):122-33. doi: 10.1016/j.jim.2011.06.023. Epub 2011 Jun 30.

PMID:
21756911
21.

Anti-galactose-α-1,3-galactose IgE from allergic patients does not bind α-galactosylated glycans on intact therapeutic antibody Fc domains.

Lammerts van Bueren JJ, Rispens T, Verploegen S, van der Palen-Merkus T, Stapel S, Workman LJ, James H, van Berkel PH, van de Winkel JG, Platts-Mills TA, Parren PW.

Nat Biotechnol. 2011 Jul 11;29(7):574-6. doi: 10.1038/nbt.1912. No abstract available.

PMID:
21747378
22.

Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII).

Klausz K, Berger S, Lammerts van Bueren JJ, Derer S, Lohse S, Dechant M, van de Winkel JG, Peipp M, Parren PW, Valerius T.

Cancer Sci. 2011 Oct;102(10):1761-8. doi: 10.1111/j.1349-7006.2011.02019.x. Epub 2011 Aug 4.

23.

Penetration of antibody-opsonized cells by the membrane attack complex of complement promotes Ca(2+) influx and induces streamers.

Beum PV, Lindorfer MA, Peek EM, Stukenberg PT, de Weers M, Beurskens FJ, Parren PW, van de Winkel JG, Taylor RP.

Eur J Immunol. 2011 Aug;41(8):2436-46. doi: 10.1002/eji.201041204. Epub 2011 Jul 4.

24.

Molecular engineering to improve antibodies' anti-lymphoma activity.

Peipp M, van de Winkel JG, Valerius T.

Best Pract Res Clin Haematol. 2011 Jun;24(2):217-29. doi: 10.1016/j.beha.2011.03.004. Epub 2011 May 7. Review.

PMID:
21658620
25.

Functional characteristics of the high affinity IgG receptor, FcγRI.

van der Poel CE, Spaapen RM, van de Winkel JG, Leusen JH.

J Immunol. 2011 Mar 1;186(5):2699-704. doi: 10.4049/jimmunol.1003526. Review.

26.

Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killing.

Lohse S, Derer S, Beyer T, Klausz K, Peipp M, Leusen JH, van de Winkel JG, Dechant M, Valerius T.

J Immunol. 2011 Mar 15;186(6):3770-8. doi: 10.4049/jimmunol.1003082. Epub 2011 Feb 11.

27.

Expression of CD64 (FcγRI) in skin of patients with acute GVHD.

van Royen-Kerkhof A, Walraven V, Sanders EA, de Weger R, van Wichen DF, de Koning E, Thepen T, van de Winkel JG, Leusen JH.

Bone Marrow Transplant. 2011 Dec;46(12):1566-9. doi: 10.1038/bmt.2010.337. Epub 2011 Jan 17.

PMID:
21243031
28.

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.

de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, Oomen LA, Peipp M, Valerius T, Slootstra JW, Mutis T, Bleeker WK, Anderson KC, Lokhorst HM, van de Winkel JG, Parren PW.

J Immunol. 2011 Feb 1;186(3):1840-8. doi: 10.4049/jimmunol.1003032. Epub 2010 Dec 27.

29.

HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20 low expressing tumor cells that resist rituximab-mediated lysis.

van Meerten T, Rozemuller H, Hol S, Moerer P, Zwart M, Hagenbeek A, Mackus WJ, Parren PW, van de Winkel JG, Ebeling SB, Martens AC.

Haematologica. 2010 Dec;95(12):2063-71. doi: 10.3324/haematol.2010.025783. Epub 2010 Sep 17.

30.

Cytokine-induced immune complex binding to the high-affinity IgG receptor, FcγRI, in the presence of monomeric IgG.

van der Poel CE, Karssemeijer RA, Boross P, van der Linden JA, Blokland M, van de Winkel JG, Leusen JH.

Blood. 2010 Dec 9;116(24):5327-33. doi: 10.1182/blood-2010-04-280214. Epub 2010 Aug 30.

31.

c-Jun activating binding protein 1 binds to the IgA receptor and modulates protein levels of FcalphaRI and FcRgamma-chain.

Bakema JE, Hiemstra IH, Bakker J, de Haij S, Kok Y, Adema G, van Egmond M, Coffer PJ, van de Winkel JG, Leusen JH.

Eur J Immunol. 2010 Jul;40(7):2035-40. doi: 10.1002/eji.200939985.

32.

In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling.

de Haij S, Jansen JH, Boross P, Beurskens FJ, Bakema JE, Bos DL, Martens A, Verbeek JS, Parren PW, van de Winkel JG, Leusen JH.

Cancer Res. 2010 Apr 15;70(8):3209-17. doi: 10.1158/0008-5472.CAN-09-4109. Epub 2010 Mar 30.

33.

Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage.

Schneider-Merck T, Lammerts van Bueren JJ, Berger S, Rossen K, van Berkel PH, Derer S, Beyer T, Lohse S, Bleeker WK, Peipp M, Parren PW, van de Winkel JG, Valerius T, Dechant M.

J Immunol. 2010 Jan 1;184(1):512-20. doi: 10.4049/jimmunol.0900847. Epub 2009 Nov 30.

34.

Fc receptors: role in biology and antibody therapy.

van de Winkel JG.

Immunol Lett. 2010 Jan 18;128(1):4-5. doi: 10.1016/j.imlet.2009.09.005. Epub 2009 Oct 4. Review.

PMID:
19808048
35.

Rapid production of recombinant human IgG With improved ADCC effector function in a transient expression system.

van Berkel PH, Gerritsen J, van Voskuilen E, Perdok G, Vink T, van de Winkel JG, Parren PW.

Biotechnol Bioeng. 2010 Feb 1;105(2):350-7. doi: 10.1002/bit.22535.

PMID:
19739094
36.

Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo.

Labrijn AF, Buijsse AO, van den Bremer ET, Verwilligen AY, Bleeker WK, Thorpe SJ, Killestein J, Polman CH, Aalberse RC, Schuurman J, van de Winkel JG, Parren PW.

Nat Biotechnol. 2009 Aug;27(8):767-71. doi: 10.1038/nbt.1553. Epub 2009 Jul 20.

PMID:
19620983
37.

Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.

Pawluczkowycz AW, Beurskens FJ, Beum PV, Lindorfer MA, van de Winkel JG, Parren PW, Taylor RP.

J Immunol. 2009 Jul 1;183(1):749-58. doi: 10.4049/jimmunol.0900632. Epub 2009 Jun 17.

38.

FcgammaRIIa genotype is associated with acute coronary syndromes as first manifestation of coronary artery disease.

Raaz D, Herrmann M, Ekici AB, Klinghammer L, Lausen B, Voll RE, Leusen JH, van de Winkel JG, Daniel WG, Reis A, Garlichs CD.

Atherosclerosis. 2009 Aug;205(2):512-6. doi: 10.1016/j.atherosclerosis.2009.01.013. Epub 2009 Jan 21.

PMID:
19232413
39.

N-linked glycosylation is an important parameter for optimal selection of cell lines producing biopharmaceutical human IgG.

van Berkel PH, Gerritsen J, Perdok G, Valbjørn J, Vink T, van de Winkel JG, Parren PW.

Biotechnol Prog. 2009 Jan-Feb;25(1):244-51. doi: 10.1002/btpr.92.

PMID:
19224598
40.

Complement activation impacts B-cell depletion by both type I and type II CD20 monoclonal antibodies.

Beurskens FJ, Ruuls SR, Engelberts PJ, Vink T, Mackus WJ, van de Winkel JG, Parren PW.

Blood. 2008 Nov 15;112(10):4354-5; author reply 4355-6. doi: 10.1182/blood-2008-07-171082. No abstract available.

41.

Experimental antibody therapy of liver metastases reveals functional redundancy between Fc gammaRI and Fc gammaRIV.

Otten MA, van der Bij GJ, Verbeek SJ, Nimmerjahn F, Ravetch JV, Beelen RH, van de Winkel JG, van Egmond M.

J Immunol. 2008 Nov 15;181(10):6829-36.

42.

Inside-out regulation of Fc alpha RI (CD89) depends on PP2A.

Bakema JE, Bakker A, de Haij S, Honing H, Bracke M, Koenderman L, Vidarsson G, van de Winkel JG, Leusen JH.

J Immunol. 2008 Sep 15;181(6):4080-8.

43.

Novel human antibody therapeutics: the age of the Umabs.

Ruuls SR, Lammerts van Bueren JJ, van de Winkel JG, Parren PW.

Biotechnol J. 2008 Oct;3(9-10):1157-71. doi: 10.1002/biot.200800110. Review.

44.

An integrated science-based approach to drug development.

Parren PW, van de Winkel JG.

Curr Opin Immunol. 2008 Aug;20(4):426-30. doi: 10.1016/j.coi.2008.06.006. Epub 2008 Jul 9. No abstract available.

PMID:
18602995
45.

Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies.

Dechant M, Weisner W, Berger S, Peipp M, Beyer T, Schneider-Merck T, Lammerts van Bueren JJ, Bleeker WK, Parren PW, van de Winkel JG, Valerius T.

Cancer Res. 2008 Jul 1;68(13):4998-5003. doi: 10.1158/0008-5472.CAN-07-6226.

46.

Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis.

Beum PV, Lindorfer MA, Beurskens F, Stukenberg PT, Lokhorst HM, Pawluczkowycz AW, Parren PW, van de Winkel JG, Taylor RP.

J Immunol. 2008 Jul 1;181(1):822-32.

47.

IL-8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in palmoplantar pustulosis.

Skov L, Beurskens FJ, Zachariae CO, Reitamo S, Teeling J, Satijn D, Knudsen KM, Boot EP, Hudson D, Baadsgaard O, Parren PW, van de Winkel JG.

J Immunol. 2008 Jul 1;181(1):669-79.

48.

Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells.

Peipp M, Lammerts van Bueren JJ, Schneider-Merck T, Bleeker WW, Dechant M, Beyer T, Repp R, van Berkel PH, Vink T, van de Winkel JG, Parren PW, Valerius T.

Blood. 2008 Sep 15;112(6):2390-9. doi: 10.1182/blood-2008-03-144600. Epub 2008 Jun 19.

49.

The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility.

Lammerts van Bueren JJ, Bleeker WK, Brännström A, von Euler A, Jansson M, Peipp M, Schneider-Merck T, Valerius T, van de Winkel JG, Parren PW.

Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):6109-14. doi: 10.1073/pnas.0709477105. Epub 2008 Apr 21. Retraction in: Lammerts van Bueren JJ, Bleeker WK, Brännström A, Jansson M, Peipp M, Schneider-Merck T, Valerius T, van de Winkel JG, Parren PW. Proc Natl Acad Sci U S A. 2012 Apr 3;109(14):5548.

50.

Treatment of rheumatoid arthritis patients with anti-TNF-alpha monoclonal antibody is accompanied by down-regulation of the activating Fcgamma receptor I on monocytes.

Wijngaarden S, van de Winkel JG, Bijlsma JW, Lafeber FP, van Roon JA.

Clin Exp Rheumatol. 2008 Jan-Feb;26(1):89-95.

PMID:
18328152

Supplemental Content

Loading ...
Support Center